GlassScriptPhysician profile
Rachel Kate Phillips
NPI 1609395946
$7,460.66
in general payments reported to CMS, 2019-2025
34 companies · $2,760 in 2025
The $2,760 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,429 · 2022: $992 · 2023: $1,332 · 2024: $948 · 2025: $2,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042 · Travel and Lodging: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.49 |
| Travel and Lodging | $997.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,319.87 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.98 | 2021-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $777.38 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $657.47 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $504.02 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $435.08 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $317.36 | 2021-2024 | Yupelri |
| Genzyme Corporation | $307.06 | 2021-2025 | |
| Harmony Biosciences LLC | $277.03 | 2021-2025 | Wakix |
| Mallinckrodt Hospital Products INC. | $215.15 | 2021-2023 | Acthar |
| Insmed, INC. | $198.67 | 2021-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $187.11 | 2022-2025 | Glassia |
| Merck Sharp & Dohme LLC | $184.09 | 2023-2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $163.49 | 2024-2025 | Dupixent |
| United Therapeutics Corporation | $161.05 | 2021-2025 | Tyvaso, Orenitram, Tyvaso |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $153.30 | 2021-2025 | |
| Baxter Healthcare | $110.51 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $86.45 | 2023-2024 | |
| Viatris Specialty LLC | $75.29 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $55.19 | 2021 | |
| Inogen, INC. | $49.91 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Axsome Therapeutics, INC. | $49.50 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $41.11 | 2021 | |
| Lilly USA, LLC | $34.88 | 2025 | Zepbound |
| Advanced Respiratory, INC | $34.27 | 2021 | |
| Amgen INC. | $34.09 | 2023-2025 | Tezspire |
| Optinose US, INC. | $24.35 | 2021 | |
| Liquidia Technologies, INC. | $23.91 | 2025 | Yutrepia |
| Verona Pharma, INC. | $21.37 | 2025 | Ohtuvayre |
| Resmed Corp | $19.91 | 2024 | |
| Shionogi INC | $19.73 | 2023 | Fetroja |
| Pfizer INC. | $15.29 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.94 | 2021 | |
| Electromed, INC. | $12.85 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.